Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 09, 2024 12:13 ET | Source: Vyome Therapeutics Inc.

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”

CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large...
January 07, 2020 07:30 ET | Source: Vyome Therapeutics Inc.

Vyome Therapeutics Strengthens Executive Management with Appointment of Craig Tooman as Chief Operating Officer and Chief Financial Officer

PRINCETON, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage company developing locally-acting, next generation therapeutics for inflammatory diseases, today announced the...
November 05, 2019 07:30 ET | Source: Vyome Therapeutics Inc.

Vyome Therapeutics Completes Enrollment of Phase 2 Clinical Trial with VB-1953 in Moderate to Severe Inflammatory Acne

PRINCETON, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant...
May 13, 2019 07:30 ET | Source: Vyome Therapeutics Inc.

Vyome Therapeutics Presents Positive Results from Two Key Clinical Trials at the 2019 Society for Investigative Dermatology Annual Meeting

PRINCETON, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant...
May 07, 2019 07:30 ET | Source: Vyome Therapeutics Inc.

Vyome Therapeutics to Present Clinical Data on VB-1953 at the 2019 Society for Investigative Dermatology Annual Meeting

PRINCETON, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant...
April 23, 2019 07:30 ET | Source: Vyome Therapeutics Inc.

Vyome Therapeutics Begins Dosing in Phase 2 Trial of VB-1953 in Moderate to Severe Inflammatory Acne Vulgaris

PRINCETON, N.J., April 23, 2019 (GLOBE NEWSWIRE) -- Vyome Therapeutics Inc., a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by...
January 03, 2019 06:00 ET | Source: Vyome Biosciences Private Limited

Vyome raises $22M to advance dermatology pipeline

PRINCETON, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Vyome Therapeutics Inc., a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by...
May 17, 2018 16:00 ET | Source: Vyome Biosciences Private Limited

Vyome Biosciences Presents Two Novel Treatments for Drug-Resistant Skin Microbes at the International Investigative Dermatology 2018 Meeting

NEW DELHI, India, May 17, 2018 (GLOBE NEWSWIRE) -- Vyome Biosciences, a clinical-stage company developing novel treatments for skin diseases caused by resistant microbes, today announced two poster...
March 12, 2018 16:01 ET | Source: Vyome Biosciences Private Limited

Vyome Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference

NEW DELHI, India, March 12, 2018 (GLOBE NEWSWIRE) -- Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant...
February 26, 2018 08:30 ET | Source: Vyome Biosciences Private Limited

Vyome Biosciences Announces Launch of Dermatology Products Through Exclusive Partnership

Vyome Partners with a Large, Global Specialty Pharmaceutical Company to Market its Dandruff Products NEW DELHI, India, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Vyome Biosciences, a clinical-stage...